The Infona portal uses cookies, i.e. strings of text saved by a browser on the user's device. The portal can access those files and use them to remember the user's data, such as their chosen settings (screen view, interface language, etc.), or their login data. By using the Infona portal the user accepts automatic saving and using this information for portal operation purposes. More information on the subject can be found in the Privacy Policy and Terms of Service. By closing this window the user confirms that they have read the information on cookie usage, and they accept the privacy policy and the way cookies are used by the portal. You can change the cookie settings in your browser.
Cancer is the second leading cause of death globally, with 9.6 million deaths yearly. As a life‐threatening disease, it necessitates the emergence of new therapies. Resistance to current chemotherapies drives scientists to develop new medications that will eventually be accessible. Because heterocycles are so common in biological substances, compounds play a big part in the variety of medications...
Studying the anticancer activity of 5‐arylidene‐2‐(4‐hydroxyphenyl)aminothiazol‐4(5H)‐ones towards cell lines of different cancer types allowed the identification of hit‐compounds inhibiting the growth of daunorubicin‐ (CEM‐DNR, IC50 = 0.32–1.28 µM) and paclitaxel‐resistant (K562‐TAX, IC50 = 0.21–1.23 µM) cell lines, with favorable therapeutic indexes. The studied compounds induced apoptosis and cellular...